Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 2/2020

01-12-2020 | Thyroid Cancer | Research article

Investigating the demographic characteristics and pathological manifestations of thyroid Cancer during the last two decades (1997–2017) in patients referred to Baqiyatallah hospital, Tehran, Iran

Authors: Majid Ramezani, Masoumeh Saeidi, Ali Zarei, Mahmoud Hasani

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Login to get access

Abstract

Background & Objective

Thyroid cancer is among the most common endocrine cancers, and its incidence in our country is in progress over the past decades. This aggravates the necessity to evaluate the changes in thyroid cancer.

Materials & methods

Through accessing the information of the records of all patients with a diagnosis of thyroid cancer between 1996 and 2017, the present study was conducted at Baqiyatallah Hospital (Tehran, Iran) according to scientific criteria. After the diagnosis, most of them also underwent surgery and were evaluated in terms of the rate of the involvement and the type of thyroid cancer, and the pathology report was recorded in their records. Information about the intended patients such as age, gender, pathologic type of cancer, associated with the patient (except thyroid cancer), and history of radiation to the patient were recorded in a standard form and subjected to statistical analysis. Demographic changes and pathological manifestations of cancers in the two decades (1997–2007) and (2007–2017) were compared. But comparisons have been made over five years.

Results

The incidence of thyroid cancer, especially papillary thyroid cancer type, was increasing at an early age, and the incidence of tumor size measuring 2–4 cm was rising. But the incidence of tumor sizes less than one centimeter declined. The amount of vascular and capsule involvement was about 3 times, and lymph node involvement was nearly 2 times. The increasing incidence of 2–4 cm tumor size in the age group of 20–50 years was more than other age groups.

Conclusion

The incidence of thyroid cancer was increasing at an early age, and the enhancement of papillary thyroid type was higher than other types. As well as, in this study, it was found that the incidence of 2–4 cm tumor sizes was rising.
Literature
2.
go back to reference Ancker OV, Krüger M, Wehland M, Infanger M, Grimm D. Review Multikinase Inhibitor Treatment in Thyroid Cancer. Int. J. Mol. Sci. 2020;21:10.CrossRef Ancker OV, Krüger M, Wehland M, Infanger M, Grimm D. Review Multikinase Inhibitor Treatment in Thyroid Cancer. Int. J. Mol. Sci. 2020;21:10.CrossRef
3.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRef Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRef
4.
go back to reference Yeh MW, Bauer AJ, Bernet VA, et al. American thyroid association statement on preoperative imaging for thyroid cancer surgery. Thyroid. 2015;25(1):3–14.CrossRef Yeh MW, Bauer AJ, Bernet VA, et al. American thyroid association statement on preoperative imaging for thyroid cancer surgery. Thyroid. 2015;25(1):3–14.CrossRef
5.
go back to reference Tufano RP, Clayman G, Heller KS, Inabnet WB, Kebebew E, Shaha A, et al. Management of recurrent / persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid. 2015;25(1):15–27.CrossRef Tufano RP, Clayman G, Heller KS, Inabnet WB, Kebebew E, Shaha A, et al. Management of recurrent / persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid. 2015;25(1):15–27.CrossRef
6.
go back to reference Dal Maso L, Tavilla A, Pacini F, et al. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. Eur J Cancer. 2017;77:140–52.CrossRef Dal Maso L, Tavilla A, Pacini F, et al. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. Eur J Cancer. 2017;77:140–52.CrossRef
7.
go back to reference Weir HK, Thompson TD, Soman A, et al. The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer. 2015 Feb 3. Weir HK, Thompson TD, Soman A, et al. The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer. 2015 Feb 3.
8.
go back to reference Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317–22.CrossRef Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317–22.CrossRef
9.
go back to reference Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013;23(7):885.CrossRef Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013;23(7):885.CrossRef
10.
go back to reference Le KT, Sawicki MP, Wang MB, Hershman JM, Leung Am. High prevalence of agent Orange exposure among thyroid Cancer patients in the National Va Healthcare System. EndocrPract. 2016; 27. Le KT, Sawicki MP, Wang MB, Hershman JM, Leung Am. High prevalence of agent Orange exposure among thyroid Cancer patients in the National Va Healthcare System. EndocrPract. 2016; 27.
11.
go back to reference Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ. 2013;347:f4706 [Medline].CrossRef Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ. 2013;347:f4706 [Medline].CrossRef
12.
go back to reference Asari R, Koperek O, Scheuba C, Riss P, Kaserer K, Hoffmann M. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. Ann Surg. 2009;249(6):1023–31 [Medline].CrossRef Asari R, Koperek O, Scheuba C, Riss P, Kaserer K, Hoffmann M. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. Ann Surg. 2009;249(6):1023–31 [Medline].CrossRef
13.
go back to reference Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on memorial sloan-kettering cancer center risk group stratification. Thyroid. 2013;23(6):683–94 [Medline].CrossRef Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on memorial sloan-kettering cancer center risk group stratification. Thyroid. 2013;23(6):683–94 [Medline].CrossRef
14.
go back to reference Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801–7.CrossRef Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801–7.CrossRef
15.
go back to reference Aschebrook-Kilfoy B, Grogan RH, Ward MH, Kaplan E, Devesa SS. Follicular thyroid cancer incidence patterns in the United States, 1980-2009. Thyroid. 2013;23(8):1015–21.CrossRef Aschebrook-Kilfoy B, Grogan RH, Ward MH, Kaplan E, Devesa SS. Follicular thyroid cancer incidence patterns in the United States, 1980-2009. Thyroid. 2013;23(8):1015–21.CrossRef
16.
go back to reference Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. Journal of cancer epidemiology. 2013;2013:1–10.CrossRef Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. Journal of cancer epidemiology. 2013;2013:1–10.CrossRef
17.
go back to reference Larijani B, Aghakhani S, Khajeh-Dini H, Baradar-Jalili R. Clinico-pathological features of thyroid cancer as observed in five referral hospitals in Iran. ActaOncologica. 2003;42(4):334–7. Larijani B, Aghakhani S, Khajeh-Dini H, Baradar-Jalili R. Clinico-pathological features of thyroid cancer as observed in five referral hospitals in Iran. ActaOncologica. 2003;42(4):334–7.
18.
go back to reference Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi AR, Tavangar SM, Malekzadeh R, et al. Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer. 2006;43(2):80.CrossRef Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi AR, Tavangar SM, Malekzadeh R, et al. Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer. 2006;43(2):80.CrossRef
19.
go back to reference Pandeya N, McLeod DS, Balasubramaniam K, Baade PD, Youl PH, Bain CJ, et al. Increasing thyroid cancer incidence in Queensland, Australia 1982-2008-true increase or overdiagnosis ? Clin Endocrinol. 2016;84(2):257–64.CrossRef Pandeya N, McLeod DS, Balasubramaniam K, Baade PD, Youl PH, Bain CJ, et al. Increasing thyroid cancer incidence in Queensland, Australia 1982-2008-true increase or overdiagnosis ? Clin Endocrinol. 2016;84(2):257–64.CrossRef
20.
go back to reference Larijani B, Aghakhani S, Haghpanah V, Mosavi-Jarrahi A, Bastanhagh MH. Review of thyroid Cancer in Iran. Austral-Asian Journal of Cancer. 2005;4(4):199–203. Larijani B, Aghakhani S, Haghpanah V, Mosavi-Jarrahi A, Bastanhagh MH. Review of thyroid Cancer in Iran. Austral-Asian Journal of Cancer. 2005;4(4):199–203.
21.
go back to reference Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomark Prev. 2009;18(3):784–91.CrossRef Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomark Prev. 2009;18(3):784–91.CrossRef
Metadata
Title
Investigating the demographic characteristics and pathological manifestations of thyroid Cancer during the last two decades (1997–2017) in patients referred to Baqiyatallah hospital, Tehran, Iran
Authors
Majid Ramezani
Masoumeh Saeidi
Ali Zarei
Mahmoud Hasani
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00617-x

Other articles of this Issue 2/2020

Journal of Diabetes & Metabolic Disorders 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.